BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29138210)

  • 1. What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.
    Hickey M; Trainer A; Braat S; Davey MA; Krejany E; Wark J
    BMJ Open; 2017 Nov; 7(11):e018758. PubMed ID: 29138210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Hickey M; Moss KM; Brand A; Wrede CD; Domchek SM; Meiser B; Mishra GD; Joffe H
    Gynecol Oncol; 2021 May; 161(2):527-534. PubMed ID: 33583580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Hickey M; Moss KM; Mishra GD; Krejany EO; Domchek SM; Wark JD; Trainer A; Wild RA
    Gynecol Oncol; 2021 Jul; 162(1):88-96. PubMed ID: 33972087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
    Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of bone density and bone strength following premenopausal risk-reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study).
    Jiang H; Robinson DL; Lee PVS; Krejany EO; Yates CJ; Hickey M; Wark JD
    Osteoporos Int; 2021 Jan; 32(1):101-112. PubMed ID: 32856124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical decision making in premenopausal
    Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
    J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):26-32. PubMed ID: 31613831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Islam RM; Davis SR; Bell RJ; Tejada-Berges T; Wrede CD; Domchek SM; Meiser B; Kirk J; Krejany EO; Hickey M
    Menopause; 2021 Mar; 28(7):748-755. PubMed ID: 33739311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
    Menopause; 2020 Jan; 27(1):20-25. PubMed ID: 31567874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
    Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
    BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
    Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
    Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    Kershaw V; Hickey I; Wyld L; Jha S
    Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():7-17. PubMed ID: 34416580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
    Gaba F; Robbani S; Singh N; McCluggage WG; Wilkinson N; Ganesan R; Bryson G; Rowlands G; Tyson C; Arora R; Saridogan E; Hanson H; Burnell M; Legood R; Evans DG; Menon U; Manchanda R;
    Int J Gynecol Cancer; 2021 Feb; 31(2):286-291. PubMed ID: 32907814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
    Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
    Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
    Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.
    Nebgen DR; Domchek SM; Kotsopoulos J; de Hullu JA; Crosbie EJ; Paramanandam VS; Brood-van Zanten MMA; Norquist BM; Guise T; Rozenberg S; Kurian AW; Pederson HJ; Yuksel N; Michaelson-Cohen R; Bober SL; da Silva Filho AL; Johansen N; Guidozzi F; Evans DG; Menon U; Kingsberg SA; Powell CB; Grandi G; Marchetti C; Jacobson M; Brennan DJ; Hickey M
    BJOG; 2023 Nov; 130(12):1437-1450. PubMed ID: 37132126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    Hickey M; Moss KM; Krejany EO; Wrede CD; Brand A; Kirk J; Symecko HL; Domchek SM; Tejada-Berges T; Trainer A; Mishra GD
    Gynecol Oncol; 2021 Oct; 163(1):148-154. PubMed ID: 34312002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    Moss KM; Mishra GD; Krejany EO; Hickey M
    Gynecol Oncol; 2022 Oct; 167(1):58-64. PubMed ID: 35933227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.
    Benshushan A; Rojansky N; Chaviv M; Arbel-Alon S; Benmeir A; Imbar T; Brzezinski A
    Climacteric; 2009 Oct; 12(5):404-9. PubMed ID: 19479488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
    Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.